LexaGene Holdings Inc. (TSX-V:LXG, OTCQB:LXXGF) has announced two purchase orders for its MiQLab Systems from Kuma Veterinary Clinic and the Emergency Veterinary Services of Roanoke.
The Beverly, Massachusetts-based molecular diagnostics company noted that the sales were closed with private hospitals.
“Veterinarians are learning more about our system and recognizing how wrong it is to have to wait days to weeks for a reference lab to provide infectious disease results that can impact the well-being of their patients,” founder and CEO Dr. Jack Regan said in a statement.
“Our MiQLab System provides them a solution to this problem, as it delivers high-quality results at the point of need in just ~2 hours. This time savings empowers them to make evidence-based decisions to improve the quality of the care they provide.”
READ: LexaGene says its largest study validates accuracy of its veterinary test panel
Gwyneth Shugart, certified veterinary technician (CVT) and co-owner of Kuma Veterinary Clinic commented: “We purchased the MiQLab system to offer better services to our clients and the pets they love.
“Too often, slow diagnostics have prevented us from more rapidly improving our patients’ health, which has led to frustration, unnecessary pain and suffering, and higher costs.”
LexaGene said the vast majority of specialty and 24-hour emergency veterinary hospitals are no longer private and are consolidated or owned by large corporations.
“Over the last two months, we’ve made good progress in the sales cycle for large corporations, where we target multi-unit sales,” LexaGene’s global director of sales and CVT Julie Griggs said.
“We expect the corporate sales will start a wave of adoption across the industry as veterinary practices will not want to be left behind and will seek to modernize their technology to keep up with the expectations of their clients and new industry standards.”
LexaGene is a molecular diagnostics company that develops systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety, and for use in open-access markets such as clinical research, agricultural testing, and biodefense.
Contact the author at stephen.gunnion@proactiveinvestors.com